References

Alhelaly MM, Soliman AM, Khaled A, Ellotf H, Attia MM, Elmaraezy A Efficacy of tranexamic acid in traumatic brain injury: Updated systematic review and meta-analysis. Trauma. 2019; 21:(3)167-175 https://doi.org/10.1177/1460408619842736

Bridgwater: Class Professional Publishing; 2019

Cornelius B, Moody K, Hopper K A retrospective study of transfusion requirements in trauma patients receiving tranexamic acid. J Trauma Nurs. 2019; 26:(3)128-133 https://doi.org/10.1097/JTN.0000000000000437

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (crash-2): A randomised, placebo-controlled trial. Lancet. 2010; 376:(9734)23-32 https://doi.org/10.1016/S0140-6736(10)60835-5

The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the crash-2 randomised controlled trial. Lancet. 2011; 377:(9771)1096-1101 https://doi.org/10.1016/S0140-6736(11)60278-X

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (crash-3): A randomised, placebo-controlled trial. Lancet. 2019; 394:(10210)1713-1723 https://doi.org/10.1016/S0140-6736(19)32233-0

Fiechtner BK, Nuttall GA, Johnson ME Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesthes Analges. 2001; 92:(5)1131-1136 https://doi.org/10.1097/00000539-200105000-00010

Fischer PE, Bulger EM, Perina DG Guidance document for the prehospital use of tranexamic acid in injured patients. Prehosp Emerg Care. 2016; 20:(5)557-559 https://doi.org/10.3109/10903127.2016.1142628

Grassin-Delyle S, Theusinger O, Albrecht R, Mueller S, Spahn D, Urien S, Stein P Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Anaesthesia. 2018; 73:(6)719-729 https://doi.org/10.1111/anae.14184

Huebner BR, Dorlac WC, Cribari C Tranexamic acid use in prehospital uncontrolled hemorrhage. Wildern Environment Med. 2017; 28:(2)S50-S60 https://doi.org/10.1016/j.wem.2016.12.006

Jawa RS, Singer A, McCormack JE, Huang EC, Rutigliano DN, Vosswinkel JA Tranexamic acid use in united states trauma centers: A national survey. Am Surg. 2016; 82:(5)439-447

Lin Z, Xiaoyi Z Tranexamic acid-associated seizures: A meta-analysis. Seizure. 2016; 36:70-73 https://doi.org/10.1016/j.seizure.2016.02.011

MIMS Online. Tranexamic Acid (Tranexamic-AFT). 2019. https://www.mimsonline.com.au/ (accessed 14 October 2019)

Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ Military application of tranexamic acid in trauma emergency resuscitation (matters) study. Arch Surg. 2012; 147:(2)113-119 https://doi.org/10.1001/archsurg.2011.287

Napolitano LM Prehospital tranexamic acid: What is the current evidence?. Trauma Surg Acute Care Open. 2017; 2:(1) https://doi.org/10.1136/tsaco-2016-000056

Neeki MM, Dong F, Toy J Tranexamic acid in civilian trauma care in the california prehospital antifibrinolytic therapy study. Western J Emerg Med. 2018; 19:(6) https://doi.org/10.5811/westjem.2018.8.39336

PATCH. PATCH-Trauma Study. 2019. https://www.patchtrauma.org/ (accessed 12 June 2020)

Paudyal P, Smith J, Robinson M Tranexamic acid in major trauma: implementation and evaluation across South West England. Eur J Emerg Med. 2017; 24:(1)44-48 https://doi.org/10.1097/MEJ.0000000000000323

Queensland Ambulance Service. Digital clinical practice manual Online: State of Queensland. 2020. https://www.ambulance.qld.gov.au/clinical.html (accessed 11 March 2020)

Roberts I Tranexamic acid in trauma: How should we use it?. J Thrombosis Haemostasis. 2015; 13:S195-S199 https://doi.org/10.1111/jth.12878

Roberts I, Edwards P, Prieto D, Joshi M, Mahmood A, Ker K, Shakur H Tranexamic acid in bleeding trauma patients: An exploration of benefits and harms. Trials. 2017; 18:(1) https://doi.org/10.1186/s13063-016-1750-1

Roberts I, Prieto-Merino D, Manno D Mechanism of action of tranexamic acid in bleeding trauma patients: An exploratory analysis of data from the crash-2 trial. Crit Care. 2014; 18:(6) https://doi.org/10.1186/s13054-014-0685-8

Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochr Database Syst Rev. 2018; https://doi.org/10.1002/14651858.CD012964

Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I The woman trial (world maternal antifibrinolytic trial): Tranexamic acid for the treatment of postpartum haemorrhage: An international randomised, double blind placebo controlled trial. Trials. 2010; 11:(1) https://doi.org/10.1186/1745-6215-11-40

Stansfield R, Morris D, Jesulola E The use of tranexamic acid (TXA) for the management of hemorrhage in trauma patients in the prehospital environment: Literature review and descriptive analysis of principal themes. Shock. 2020; 53:(3)277-283 https://doi.org/10.1097/SHK.0000000000001389

Strosberg DS, Nguyen MC, Mostafavifar L, Mell H, Evans DC Development of a prehospital tranexamic acid administration protocol. Prehosp Emerg Care. 2016; 20:(4)462-466 https://doi.org/10.3109/10903127.2015.1128033

St John New Zealand. Clinical Procedures and Guidelines, Pocket Edition, 2019–2022. 2019. https://www.stjohn.org.nz/globalassets/documents/health-practitioners/clinical-procedures-and-guidelines—pocket-edition.pdf (accessed 1 June 2020)

Wafaisade A, Lefering R, Bouillon B, Böhmer AB, Gäßler M, Ruppert M, DGU T Prehospital administration of tranexamic acid in trauma patients. Crit Care. 2016; 20:(1) https://doi.org/10.1186/s13054-016-1322-5

Tranexamic acid and international ambulance services

02 June 2020
Volume 10 · Issue 2

Abstract

Introduction:

Severe haemorrhage may lead to pathologic release of fibrinolytic enzymes, which break down blood clots. Tranexamic acid (TXA) is a drug that inhibits the fibrinolysis of blood clots.

Aim:

The purpose of this review is to explore current literature regarding prehospital TXA administration for patients suffering severe haemorrhage following trauma, and to discuss whether this drug should be more widely used across modern international ambulance services.

Methods:

Literature searches of EBSCO Host, ProQuest and PubMed databases were conducted in August, 2019.

Results:

TXA administration within 3 hours following injury is associated with improved outcomes for severe haemorrhage patients. However, there are reservations that the success of TXA in developing countries and military settings may not be directly transferrable to the modern civilian healthcare systems.

Discussion:

The benefits of prehospital TXA administration appear compelling. Further studies will help guide wider international implementation of this drug in paramedic practice.

Haemorrhagic shock is a leading cause of death internationally, whether from serious trauma (Grassin-Delyle et al, 2018; Neeki et al, 2018) or other conditions such as postpartum haemorrhage (Shakur et al, 2010; Cannon, 2018). Severe haemorrhage can compromise the body's ability to form and maintain clots. This is because haemorrhage, hypoperfusion and haemorrhagic shock may result in dysregulation of coagulation systems, through pathologic release of fibrinolytic enzymes. These fibrinolytic enzymes have the effect of prematurely breaking down clots within the haemorrhaging patient, thereby compromising haemodynamic stability through excessive thrombolysis (Huebner et al, 2017; Grassin-Delyle et al, 2018; Neeki et al, 2018).

Tranexamic acid (TXA) inhibits the premature breakdown of blood clots, which may occur following severe haemorrhage. TXA is a synthetic derivative of lysine that inhibits the fibrinolysis of blood clots (Roberts, 2015; Jawa et al, 2016; MIMS, 2019). TXA appears to be a promising drug that—if administered early, such as during the prehospital phase of care—may reduce mortality from severe haemorrhage (Stansfield et al, 2020). In the United Kingdom (UK), TXA was first introduced to the South Western Ambulance Service Trust in December, 2011 (Paudyal et al, 2017) and has since become widely used by paramedics across the UK when treating patients with severe internal or external haemorrhage, postpartum haemorrhage and head injury (Association of Ambulance Chief Executives, 2019). However, other studies suggest that further research is required to demonstrate the efficacy of prehospital TXA administration (Napolitano, 2017), and it is perhaps for this reason that TXA is not yet widely used across all international ambulance services. For example, TXA administration across Australian ambulance services is largely restricted to the PATCH (2019) research study, while paramedic use of this drug in New Zealand has only recently commenced (St John New Zealand, 2019).

Subscribe to get full access to International Paramedic Practice

Thank you for visiting International Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.

What's included

  • CPD Focus

  • Develop your career

  • Stay informed